1706525-09-8

Basic information

• Product Name: N⁶-[(5-bromothiophen-2-yl)methyl]adenosine
• CAS NO: 1706525-09-8
• Molecular Weight: 442.293
• Mol File: 1706525-09-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N⁶-[(5-bromothiophen-2-yl)methyl]adenosine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁶-[(5-bromothiophen-2-yl)methyl]adenosine(1706525-09-8)
• EPA Substance Registry System: N⁶-[(5-bromothiophen-2-yl)methyl]adenosine(1706525-09-8)

Safety Data

• Hazardous Substances Data: 1706525-09-8(Hazardous Substances Data)

Upstream product

• 362-75-4 2',3'-isopropylidene adenosine 
• 139301-93-2 9-((3aR,4R,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-amine 
• 612499-04-4 (5-bromothiophen-2-yl) methanamine 
• 2004-06-0 6-Chloropurine riboside 

Relevant articles and documents

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N6-[(3-halothien-2-yl)methyl]adenosine, N6-[(4-halothien-2-yl)methyl]adenosine, and N6-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N6-[(2-bromothien-3-yl)methyl]adenosine, N6-[(4-bromothien-3-yl)methyl]adenosine, N6-[(5-bromothien-3-yl)methyl]adenosine N6-[(2-chlorothien-3-yl)methyl]adenosine, N6-[(4-chlorothien-3-yl)methyl]adenosine, and N6-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting ofN 6 -[(3-halothien-2-yl)methyl]adenosine,N 6 -[(4-halothien-2-yl)methyl]adenosine, andN 6 -[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting ofN 6 -[(2-bromothien-3-yl)methyl]adenosine,N 6 -[(4-bromothien-3-yl)methyl]adenosine,N 6 -[(5-bromothien-3-yl)methyl]adenosineN 6 -[(2-chlorothien-3-yl)methyl]adenosine,N 6 -[(4-chlorothien-3-yl)methyl]adenosine, andN 6 -[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.